The biopharma industry experienced a lack of mergers & acquisitions (M&A) activity in 2024, with total values dropping by 51% despite a 17% increase in transactions. However, 2025 is expected to witness a surge in M&A dealmaking, due to factors such as patent expirations, changing political landscape, and companies’ need to diversify their portfolios and access new technologies. Experts believe large biopharma firms have reserved $1.3 trillion for such deals.
Cyber incident at Ontario’s largest school board involves data going back to 1985 – Global News Toronto
A cyber incident occurred at Ontario’s largest school board, involving data dating back to 1985. Global News Toronto reported on the breach of data at
